Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Phase 2 Terminated 7 enrolled Brown University

NaSingle-groupOpen-labelTreatment

Summary

will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study

Timeline

Start: 2012-11
Primary completion: 2013-10
Completion: 2013-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naltrexone	Small molecule	5 mg	—

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Summary

Timeline

Drugs

Indications